301 related articles for article (PubMed ID: 25900171)
1. Oritavancin: A Long-Half-Life Lipoglycopeptide.
Saravolatz LD; Stein GE
Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
[TBL] [Abstract][Full Text] [Related]
2. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
3. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Crandon J; Nicolau DP
Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
[TBL] [Abstract][Full Text] [Related]
4. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
5. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Bouza E; Burillo A
Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin for acute bacterial skin and skin structure infections.
Messina JA; Fowler VG; Corey GR
Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
[TBL] [Abstract][Full Text] [Related]
8. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
9. Oritavancin: A Novel Lipoglycopeptide.
Mattox J; Belliveau P; Durand C
Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
[TBL] [Abstract][Full Text] [Related]
10. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
[TBL] [Abstract][Full Text] [Related]
12. Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
[TBL] [Abstract][Full Text] [Related]
13. Oritavancin: a long-acting antibacterial lipoglycopeptide.
Kaasch AJ; Seifert H
Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
15. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
16. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
17. Oritavancin: an investigational lipoglycopeptide antibiotic.
Karaoui LR; El-Lababidi R; Chahine EB
Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
[TBL] [Abstract][Full Text] [Related]
18. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
19. Oritavancin: a review in acute bacterial skin and skin structure infections.
Syed YY; Scott LJ
Drugs; 2015 Nov; 75(16):1891-902. PubMed ID: 26464319
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
